Public offering

ZM UPCOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Zoom Video Communications, Inc. Short Sellers, Long and Derivative Investors of Class Action and Lead Plaintiff Deadline: June 8, 2020

Tuesday, June 2, 2020 - 5:00pm

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
  • On or around April 18, 2019, Zoom conducted its initial public offering (IPO), selling 9.91 million shares priced at $46 per share.
  • Then, on March 31, 2020,The Interceptreported that Zooms video conferencing software is not, in fact, end-to-end encrypted between meeting participants, contrary to the Companys suggestion.
  • If you suffered a loss in Zoom you have until June 8, 2020 to request that the Court appoint you as lead plaintiff.

Vroom Announces Launch of Initial Public Offering

Tuesday, June 2, 2020 - 11:30am

Vroom, Inc. (Vroom), the online automotive retailer, today announced that it has commenced the initial public offering of its common stock.

Key Points: 
  • Vroom, Inc. (Vroom), the online automotive retailer, today announced that it has commenced the initial public offering of its common stock.
  • Vroom is offering 18,750,000 shares of its common stock.
  • The initial public offering price is expected to be between $15.00 and $17.00 per share.
  • Vroom expects to grant the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the initial public offering price to cover over-allotments.

Guardant Health Announces Pricing of Upsized Public Offering

Tuesday, June 2, 2020 - 3:32am

The public offering was increased from the previously announced offering size of 10,000,000 shares of common stock.

Key Points: 
  • The public offering was increased from the previously announced offering size of 10,000,000 shares of common stock.
  • In addition, Guardant Health and SoftBank Investment Advisers have granted the underwriter a 30-day option to purchase up to 1,725,000 additional shares of common stock (562,500 additional shares from Guardant Health and 1,162,500 additional shares from SoftBank Investment Advisers) at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering to Guardant Health, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $315.0 million.
  • Guardant Health intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Guardant Health, primarily for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters and capital expenditures.

Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

Tuesday, June 2, 2020 - 2:30am

LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $7.50 per share.

Key Points: 
  • LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $7.50 per share.
  • In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on June 4, 2020, subject to customary closing conditions.
  • The securities described above were offered by Kaleido pursuant to a shelf registration statement on Form S-3 (No.

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Tuesday, June 2, 2020 - 2:05am

SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share.
  • The gross proceeds from this offering are expected to be approximately $550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.
  • In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Jefferies LLC and Cowen and Company, LLC are acting as joint lead book-running managers for the offering.

DIGITAL ALLY ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Monday, June 1, 2020 - 11:48pm

In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any.

Key Points: 
  • In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security.
  • For additional news and information please visit www.digitalallyinc.com or follow additional Digital Ally Inc. social media channels here:

Guardant Health Announces Proposed Public Offering of Common Stock

Monday, June 1, 2020 - 9:37pm

In addition, Guardant Health and SoftBank Investment Advisers expect to grant the underwriter a 30-day option to purchase up to 1,500,000 additional shares of common stock (450,000 additional shares from Guardant Health and 1,050,000 additional shares from SoftBank Investment Advisers) at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Guardant Health and SoftBank Investment Advisers expect to grant the underwriter a 30-day option to purchase up to 1,500,000 additional shares of common stock (450,000 additional shares from Guardant Health and 1,050,000 additional shares from SoftBank Investment Advisers) at the public offering price, less underwriting discounts and commissions.
  • Guardant Health intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Guardant Health, primarily for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters and capital expenditures.
  • Guardant Health will not receive any proceeds from the sale of shares in the offering by SoftBank Investment Advisers.
  • These statements include statements regarding the proposed offering of Guardant Healths common stock, the timing and size of and mix of primary and secondary shares in the proposed offering, the grant of the option to purchase additional shares and the anticipated use of the net proceeds from the proposed offering.

OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock

Monday, June 1, 2020 - 9:01pm

BETHLEHEM, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (OraSure or the Company) today announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock.

Key Points: 
  • BETHLEHEM, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (OraSure or the Company) today announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock.
  • are acting as joint book running managers of the offering and as representatives of the underwriters.
  • The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock offered in the public offering.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

Monday, June 1, 2020 - 9:01pm

RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.
  • The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters option to purchase additional shares, were approximately $115 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.
  • J.P. Morgan and Piper Sandler acted as joint book-running managers for the offering.
  • A prospectus supplement relating to the offering has been filed with the SEC and is available on its website at www.sec.gov.

Zomedica Pharmaceuticals Corp. Closes $20 Million Public Offering

Friday, May 29, 2020 - 9:05pm

ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (Zomedica or the Company), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant.

Key Points: 
  • ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (Zomedica or the Company), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant.
  • The gross proceeds from this offering are approximately $20.0 million, before deducting placement agents fees and other estimated offering expenses payable by the Company, assuming none of the warrants sold in this offering are exercised for cash.
  • The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No.
  • 333-238322) previously filed with and declared effective by the Securities and Exchange Commission (the SEC) on May 26, 2020.